Goldenwell Biotech (Goldenwell Biotech) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Goldenwell Biotech Change In Receivables?

Goldenwell Biotech's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Goldenwell Biotech's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Goldenwell Biotech's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Goldenwell Biotech's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Goldenwell Biotech's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Goldenwell Biotech's liquidation value for the three months ended in Mar. 2024 was $-0.03 Mil.

Goldenwell Biotech Change In Receivables Historical Data

The historical data trend for Goldenwell Biotech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Goldenwell Biotech Change In Receivables Chart

Goldenwell Biotech Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Goldenwell Biotech Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial										-	-	-	-	-

Goldenwell Biotech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Goldenwell Biotech (OTCPK:GWLL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Goldenwell Biotech's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Goldenwell Biotech's accounts receivable are only considered to be worth 75% of book value:

Goldenwell Biotech's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.024	-	0.145	+	0.75 * 0	+	0.5 * 0.175
=	-0.03

Goldenwell Biotech Change In Receivables Related Terms

Thank you for viewing the detailed overview of Goldenwell Biotech's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Goldenwell Biotech (Goldenwell Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Goldenwell Biotech Inc (OTCPK:GWLL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

2071 Midway Drive, Twinsburg, OH, USA, 44087

Website

https://www.goldenwellbiotech.com

Goldenwell Biotech Inc is engaged in the research and development, production and sales of health care and supplements products. Its products comprise JI MAI - Bovine Cardiac Vascular Active Peptide, Double Proline AG - 3D Active Collagen Peptide, Cartilage Peptide - Type II collagen peptide, and Sugar Master.

Executives

Li Yang	director, 10 percent owner, officer: Treasurer	C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087
Hua Xie	director, officer: Secretary	C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087
Shuang Liu	director, 10 percent owner, officer: Chief Executive Officer	C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087

Goldenwell Biotech (Goldenwell Biotech) Headlines

No Headlines